ArticleNeurology. Clinical practice2019
Primary headache disorders: Five new things.
Article in Neurology. Clinical practice, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 34 citations in OpenAlex.
- Article
- Orexins and primary headaches: an overview of the neurobiology and clinical impact.Expert review of neurotherapeutics · 2024Review
- Headaches during pregnancy and the risk of subsequent stroke.The journal of headache and pain · 2023Article
- Article
- Diagnosis, consultation, treatment, and impact of migraine in the US: Results of the OVERCOME (US) study.Headache · 2022Article
- Multinational descriptive analysis of the real-world burden of headache using the Migraine Buddy application.European journal of neurology · 2021Article
- Efficacy of ketamine in the treatment of migraines and other unspecified primary headache disorders compared to placebo and other interventions: a systematic review.Journal of dental anesthesia and pain medicine · 2021Review
- Predicting the response to a triptan in migraine using deep attack phenotyping: A feasibility study.Cephalalgia : an international journal of headache · 2021Article
- [Primary headaches : Neglected or overrated?]Schmerz (Berlin, Germany) · 2020Article
- Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache.Cephalalgia : an international journal of headache · 2020Article
- The fifth cranial nerve in headaches.The journal of headache and pain · 2020Review
- Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache.Brain sciences · 2020Review
- Spotlight on headache.Neurology. Clinical practice · 2019Article
Corrections and comments
- Commented on by
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo review 5 new areas in primary headache disorders, especially migraine and cluster headache. RECENT
findingsCalcitonin gene-related peptide (CGRP) receptor antagonists (gepants-rimegepant and ubrogepant) and serotonin 5-HT SUMMARY: Headache medicine has made remarkable strides, particularly in understanding migraine and cluster headache in the past 5 years. For the most common reason to visit a neurologist, therapeutic advances offer patients reduced disability and neurologists a rewarding, key role in improving the lives of those with migraine and cluster headache.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.